TL;DR
This study investigated the prevalence and impact of rare genetic variants associated with hypertrophic cardiomyopathy (HCM) in a large, general adult population. They found that while these variants are not highly penetrant for overt HCM, they significantly increase the risk of adverse cardiovascular outcomes, even in individuals without diagnosed cardiomyopathy. This highlights the potential for genetic screening to improve risk stratification beyond traditional familial assessments.
What Problem Does This Paper Address?
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition primarily caused by mutations in genes that encode sarcomere proteins. While it's known that these mutations increase the risk of serious cardiovascular events like heart failure and sudden cardiac death, much of the existing research focuses on individuals already diagnosed with HCM or their families. This leaves a significant gap in understanding the true prevalence and clinical impact of these "rare genetic variants" in the broader, seemingly healthy adult population. Specifically, the paper aims to answer:
- How common are these HCM-associated genetic variants in the general adult population?
- What are the actual cardiovascular outcomes and phenotypic expressions (like heart muscle thickening) associated with these variants in individuals who don't have a diagnosed HCM?
- Can identifying these variants in the general population help us better predict future cardiovascular risks, even before overt disease develops?
Methods
The researchers utilized data from the UK Biobank, a large-scale biomedical research resource. Their approach involved several key steps:
- Whole Exome Sequencing (WES): They analyzed the entire protein-coding region of the genome for over 200,000 participants to identify rare genetic variants.
- Variant Classification: Variants were categorized into three groups:
- SARC-HCM-P/LP: Pathogenic or likely pathogenic variants definitively linked to HCM.
- SARC-IND: Variants of indeterminate significance, which might contribute to HCM, dilated cardiomyopathy (DCM), or have minimal impact.
- SARC-NEG: Genotype-negative individuals with no rare variants in HCM-associated genes.
- Cardiac Magnetic Resonance Imaging (CMR): A subset of participants underwent CMR scans to assess detailed cardiac structure and function.
- Advanced Image Analysis (Deep Learning): A novel deep learning neural network was employed for precise, automated segmentation of cardiac images. This allowed for highly accurate measurements of left ventricular wall thickness, chamber volumes, and myocardial strain, surpassing the reliability of human experts in some aspects.
- Outcome Analysis: Lifetime risk of adverse cardiovascular events (death, heart failure, arrhythmia, stroke, cardiac arrest) was assessed using Cox proportional hazards models, adjusted for various clinical factors.
Datasets
- UK Biobank (UKBB): This study primarily used data from the UK Biobank, a prospective cohort study of over 500,000 UK residents aged 40-69 years at recruitment.
- WES Data: Used for 200,584 participants.
- CMR Data: Used for 39,551 participants.
- Combined WES and CMR Data: Used for 21,322 participants for detailed phenotypic analysis.
Key Insights and Ideas
- Low Penetrance, High Risk: The most striking finding is that while rare, pathogenic HCM variants (SARC-HCM-P/LP) are not highly "penetrant" (meaning they don't always lead to overt HCM), they are strongly associated with an increased risk of adverse cardiovascular outcomes. This suggests that the genetic predisposition can manifest as increased risk even without the classic signs of heart muscle thickening.
- Subtle Phenotypic Changes: Even in individuals without diagnosed HCM, SARC-HCM-P/LP variants were linked to subtle changes in heart structure, such as an asymmetric increase in left ventricular wall thickness and concentric remodeling. This indicates that the genetic variants are indeed influencing cardiac physiology, albeit not always to the point of a clinical diagnosis.
- SARC-IND Variants are Benign (in aggregate): Variants of indeterminate significance (SARC-IND) did not show an increased risk of adverse outcomes compared to the SARC-NEG group. This suggests that, as a group, these variants are less concerning, though individual variants within this category might still warrant further investigation.
- Sex Differences in Risk: The increased risk associated with SARC-HCM-P/LP variants was more pronounced in women, highlighting potential sex-specific biological mechanisms or differential responses to genetic predisposition.
- Genetics as a Complementary Risk Factor: The study underscores that genetic assessment can add significant value to traditional risk stratification, particularly for individuals with unexplained hypertrophy or those at risk for cardiovascular events, even without a family history of HCM.
Key Results
- Prevalence: Rare variants in HCM-associated sarcomere-encoding genes were found in 2.9% of participants (1 in 35). Pathogenic or likely pathogenic variants (SARC-HCM-P/LP) were present in 0.25% (1 in 407).
- Outcomes: SARC-HCM-P/LP variants were associated with a 1.69-fold increased risk of death or major adverse cardiac events (MACE), primarily driven by a 4.23-fold increased risk of heart failure.
- Phenotype: In individuals with SARC-HCM-P/LP variants, left ventricular wall thickness was increased. However, overt hypertrophy (≥13 mm) was only present in 18.4% of these individuals.
- Heart Failure Risk: Even after adjusting for wall thickness, SARC-HCM-P/LP variants remained significantly associated with an increased risk of heart failure (HR: 6.74).
Limitations and Future Work
- Population Bias: The UK Biobank population is predominantly European, limiting the generalizability of findings to other ethnicities. The study also acknowledges potential selection bias, as younger and more severely affected individuals might be underrepresented.
- Lack of Familial Data: The study did not have access to detailed family history or co-segregation data, which could provide further insights into variant penetrance and inheritance patterns.
- Variant Classification Nuances: While efforts were made to classify variants rigorously, the SARC-IND category inherently contains a mix of variants with varying clinical implications.
- Future Directions: The authors suggest that further genomic analyses are needed to characterize specific risks and complication types associated with various inherited forms of HCM. They also emphasize the importance of improved understanding of the clinical significance of these variants for risk stratification and management, especially in light of recommendations for active screening of secondary findings during clinical sequencing.
Summary updated